Autoimmune lymphoproliferative syndrome type III: An indefinite disorder

被引:9
作者
ten Bosch, JV [1 ]
Otten, J [1 ]
Thielemans, K [1 ]
机构
[1] Univ Libre Brussels, Dept Physiol, B-1090 Brussels, Belgium
关键词
ALPS type III; Fas; apoptosis; diagnostic aspects;
D O I
10.3109/10428190109057954
中图分类号
R73 [肿瘤学];
学科分类号
100214 ;
摘要
Autoimmune Lymphoproliferative Syndrome (ALPS) is a childhood disorder characterized by chronic nonmalignant lymphoproliferation and autoimmunity. Although the pathogenesis is not fully understood. deficient Fas mediated apoptosis appears to be an important factor. This deficiency can be caused by a mutation of the: APT1 gene (ALPS type Ia), of the FasL gene (ALPS type Ib). or of the Caspase-10 gene (ALPS type II). In one sub population of patients, no mutations have been identified as: yet (ALPS type III). According to published data, the latter group is much smaller than the group of patients with ALPS type Ia. However. because of the variability of the clinical presentation and the absence of a known genetic defect, this disease is difficult to diagnose, the more so as few data have been reported on these patients. Thus, ALPS type III could be more common than believed until now. In this review we provide evidence for this hypothesis.
引用
收藏
页码:55 / +
页数:12
相关论文
共 65 条
[1]   Fas-induced activation of the cell death-related protease CPP32 is inhibited by Bcl-2 and by ICE family protease inhibitors [J].
Armstrong, RC ;
Aja, T ;
Xiang, JL ;
Gaur, S ;
Krebs, JF ;
Hoang, K ;
Bai, X ;
Korsmeyer, J ;
Karanewsky, DS ;
Fritz, LC ;
Tomaselli, KJ .
JOURNAL OF BIOLOGICAL CHEMISTRY, 1996, 271 (28) :16850-16855
[2]   Identification of new Fas mutations in a patient with autoimmune lymphoproliferative syndrome (ALPS) and eosinophilia [J].
Aspinall, AI ;
Pinto, A ;
Auer, IA ;
Bridges, P ;
Luider, J ;
Dimnik, L ;
Patel, KD ;
Jorgenson, K ;
Woodman, RC .
BLOOD CELLS MOLECULES AND DISEASES, 1999, 25 (15) :227-238
[3]  
Bader-Meunier B, 2000, BRIT J HAEMATOL, V108, P300
[4]   Missense mutations in the Fas gene resulting in autoimmune lymphoproliferative syndrome: A molecular and immunological analysis [J].
Bettinardi, A ;
Brugnoni, D ;
QuirosRoldan, E ;
Malagoli, A ;
LaGrutta, S ;
Correra, A ;
Notarangelo, LD .
BLOOD, 1997, 89 (03) :902-909
[5]   Bcl-x(L) can inhibit apoptosis in cells that have undergone Fas-induced protease activation [J].
Boise, LH ;
Thompson, CB .
PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF THE UNITED STATES OF AMERICA, 1997, 94 (08) :3759-3764
[6]   A NOVEL PROTEIN THAT INTERACTS WITH THE DEATH DOMAIN OF FAS/APO1 CONTAINS A SEQUENCE MOTIF RELATED TO THE DEATH DOMAIN [J].
BOLDIN, MP ;
VARFOLOMEEV, EE ;
PANCER, Z ;
METT, IL ;
CAMONIS, JH ;
WALLACH, D .
JOURNAL OF BIOLOGICAL CHEMISTRY, 1995, 270 (14) :7795-7798
[7]   Involvement of MACH, a novel MORT1/FADD-interacting protease, in Fas/APO-1- and TNF receptor-induced cell death [J].
Boldin, MP ;
Goncharov, TM ;
Goltsev, YV ;
Wallach, D .
CELL, 1996, 85 (06) :803-815
[8]   CHRONIC LYMPHADENOPATHY SIMULATING MALIGNANT LYMPHOMA [J].
CANALE, VC ;
SMITH, CH .
JOURNAL OF PEDIATRICS, 1967, 70 (06) :891-+
[9]   FADD, A NOVEL DEATH DOMAIN-CONTAINING PROTEIN, INTERACTS WITH THE DEATH DOMAIN OF FAS AND INITIATES APOPTOSIS [J].
CHINNAIYAN, AM ;
OROURKE, K ;
TEWARI, M ;
DIXIT, VM .
CELL, 1995, 81 (04) :505-512
[10]   Selective induction of apoptosis in mature T lymphocytes by variant T cell receptor ligands [J].
Combadiere, B ;
Sousa, CRE ;
Germain, RN ;
Lenardo, MJ .
JOURNAL OF EXPERIMENTAL MEDICINE, 1998, 187 (03) :349-355